Lyra Therapeutics, Inc.LYRANASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+90.3%
5Y CAGR+42.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+90.3%/yr
Annual compound
5Y CAGR
+42.7%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
5.9x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2024 | $97.88M | +42.5% |
| 2023 | $68.68M | +19.1% |
| 2022 | $57.67M | +305.9% |
| 2021 | $14.21M | +46.7% |
| 2020 | $9.69M | -41.4% |
| 2019 | $16.52M | +94.3% |
| 2018 | $8.50M | - |